Pixelgen Technologies, a Stockholm, Sweden-based company which specializes in spatial proteomics for single cells, raised approximately $7.3M in Series A funding.
The round was led by Industrifonden and Navigare Ventures.
The company intends to use the funds to support the commercial expansion of its recently launched spatial proteomics tool, which analyzes cell surface proteins on single cells to transform drug discovery and basic science.
Led by CEO Simon Fredriksson, Pixelgen Technologies has developed Molecular Pixelation, a DNA-based visualization technology platform for analyzing cell surface proteins, to gain insights into cellular activity that will advance better medicines and diagnostics.
In conjunction with the financing, Industrifonden Senior Investment Director Patrik Sobocki, Ph.D., will join Pixelgen’s board of directors. Sobocki brings decades of experience in healthcare, technology, and entrepreneurship to the board, in addition to his background in international research and development and commercial leadership roles in global pharmaceutical companies.
FinSMEs
09/10/2023